SmartDyeLivery develops functionalized nanoparticles in which therapeutic compounds are enveloped and safely transported to specific organs, which the medicines are targeting. This patented platform delivery technology can be used for a wide range of therapeutic applications and also allows for a unique theranostic use case. Currently the SmartDyeLivery team is focusing on a therapy for sepsis induced liver failure with the goal of reducing the mortality rate of such cases by 90%.
About bm‑t: Erfurt-based, beteiligungsmanagement Thüringen (bm|t) – a subsidiary of the Thuringia Development Bank, is the first address for investments in Thuringia, Germany. bm‑t currently manages eight investment funds with a total volume of 320M EUR. bm‑t invests in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.
About SmartDyeLivery GmbH: SmartDyeLivery GmbH develops nanoparticle transport for therapeutic, diagnostic, and theranostic applications. The company´s goal is to save patients´ lives by creating new therapy options for medical conditions that were previously either untreatable or extremely difficult to treat.
You can find more information about SmartDyeLivery at www.smartdyelivery.de